Anti-infectives

Increasing microbial resistance is creating a demand for new drugs, which is currently not matched by privately-funded research and development, making it all the more important to obtain protection with smart, cost effective IP strategies for novel inventions addressing the innovation void.  

The repurposing of drugs can also be protected by patents, which requires experience and expertise in second-medical use claims to provide the best possible support. 

Universities and research institutions, start-up companies and SMEs all benefit from the wide-ranging, commercially relevant experience of HGF’s anti-infectives IP team, who possess deep knowledge and understanding of the shifting patent laws that affect innovators in areas relating to anti-infective agents.  

HGF’s specialist attorneys combine extensive legal, scientific and transactional expertise with in-house backgrounds to develop multijurisdictional IP protection strategies across antibiotics, antivirals, immunomodulators and vaccines, as well as diagnostic methods and technologies.  

The anti-infectives team specialises in patent and trade mark protection, with targeted and industry-validated advice on drafting and prosecuting, including second medical use type claims and cross jurisdictional drafting of patent applications. Furthermore, the attorneys are highly accomplished across oppositions and appeals in biologics, small molecule drugs and diagnostic devices, freedom-to-operate analysis, in-and-out licensing and supplementary protection certificates (SPCs).

Latest updates

Event - 29th November 2022

LSPN Europe 2022

HGF is a silver sponsor of LSPN Europe 2022 on 29th November in London. This event will explore some of the biggest challenges facing the Life Sciences Patent Community right now …

Event details

Food technology companies and investors - the value of IP landscape analysis

Case study – alt fat innovation Many companies and investors are aware of the importance of identifying and protecting their innovations, and in particular of the importance of obtaining patents …

Read article
Event - 22nd September 2022

BioCap Conference 2022

HGF is a gold sponsor at the BioCap Conference 2022. The conference will be held on Thursday 22 September at the Alderley Park Conference Centre. It connects life sciences businesses, …

Event details

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

The Microbiome Times: ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

HGF Partner and Patent Attorney Craig Thomson and Patent Director Dr Jennifer Bailey write an article for The Microbiome Times on ELIGO v SNIPR: a reflection on IP strategies in …

Read article

Getting your first filing right

One of the most often asked questions of patent attorneys is “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our anti-infectives specialists.